Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEvgen Pharma Share News (EVG)

Share Price Information for Evgen Pharma (EVG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
EVG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

Fri, 09th Feb 2024 17:02

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

The divergence between markets in Europe and New York was perhaps typified by the S&P 500 hitting a record high, cementing its status above the 5,000 point threshold.

The greenback ended the week by returning gains, meanwhile, as a government release denoting consumer price index reading revisions offered little to dollar bulls.

The FTSE 100 index closed down 22.90 points, 0.3%, at 7,572.58. The FTSE 250 ended 40.40 points lower, 0.2%, at 19,062.32, and the AIM All-Share lost 3.69 points, 0.5%, at 747.41.

For the week, both the FTSE 100 and FTSE 250 lost 0.6%, while the AIM All-Share gave back 0.9%

The Cboe UK 100 ended down 0.3% at 756.87, the Cboe UK 250 fell 0.5% to 16,463.05, and the Cboe Small Companies lost 0.3% to 14,534.93.

In European equities on Friday, both the CAC 40 in Paris and the DAX 40 in Frankfurt ended down 0.2%.

In New York, the Dow Jones Industrial Average was down 0.13%, while the S&P 500 added 0.3% and the Nasdaq Composite surged 0.9%.

Having very briefly topped the threshold on Thursday, the S&P 500 opened above 5,000 points on Friday.

"While the Nasdaq 100 and S&P 500 are making new record highs, the latter topping the 5,000 mark, European stock indices found it difficult to keep up and have had a slightly negative end to the week. The FTSE 100 in particular suffered a third straight day of losses ahead of next week's UK unemployment, inflation, Q4 GDP and retail sales data," IG analyst Axel Rudolph commented.

The unemployment, inflation and economic growth readings will be closely eyed by the Bank of England, with the next interest rate decision from Threadneedle Street around six weeks away.

The UK inflation data is released on Wednesday, though there is another reading before the BoE's next decision on March 20.

US inflation data for January is released on Tuesday. According to consensus cited by FXStreet, the annual consumer price inflation rate is expected to have cooled to 3.0% in January, from 3.4% in December.

US inflation data from the end of last year saw little in the way of revisions, according to new data published Friday.

The Bureau of Labor Statistics made minimal revisions to last year's inflation data, with consumer prices excluding food and energy items rising at a 3.3% annualised rate in the final three months of 2023, matching the previous reading.

Revisions to the headline figure were also minimal. December's monthly increase was marked down to a 0.2% advance instead of 0.3%, while the reading for November moved up 0.1 percentage point, also to 0.2%.

The dollar fell back after the figures, which were seen as supporting an interest rate cut in May.

Federal Reserve Chair Jerome Powell and his colleagues have said they need to see more evidence that price pressures are sustainably receding before they begin cutting interest rates.

In late January, Powell eroded hopes for a cut in interest rates in March, saying it is not the "most likely case."

The pound was quoted at USD1.2632 late on Friday in London, up compared to USD1.2609 at the equities close on Thursday. The euro stood at USD1.0783, up against USD1.0763. Against the yen, the dollar was trading at JPY149.31, down from JPY149.39.

In London, there was little in the way of major large-cap moves, with Fresnillo closing among the worst FTSE 100 performers. The gold miner ended down 3.4%, tracking bullion prices lower.

"After a barrage of company announcements this week, it's no wonder that markets have paused for breath on Friday. Investors have had so much to take in from a wealth of big names that they're exhausted by the all the numbers," AJ Bell analyst Russ Mould commented.

Gold was quoted at USD2,021.73 an ounce late Friday afternoon, down against USD2,029.31 late Thursday and off the USD2,034.63 it fetched this time last week. Gold traded as low as below the USD2,015 mark earlier this week.

ACY Securities analyst Luca Santos commented: "Gold, the age-old symbol of wealth and stability, has recently faced a significant challenge, breaking below a crucial technical support level at USD2.017 per ounce. This development sends a negative signal for both gold and silver. There is even a possibility of a further slide to the mid USD1.980 per ounce level, indicating a challenging period for gold investors."

Recently the object of takeover interest, packaging firm DS Smith and housebuilder Redrow climbed 2.5% and 0.3%, extending gains. Peer Mondi is mulling a takeover of DS Smith, while Redrow has agreed to a housebuilding tie-up with Barratt Developments.

There was some more dealmaking on Friday.

Barclays is to buy the retail banking business of Tesco Bank, as the big UK supermarkets scale back their forays into financial services.

Tesco said it will sell to Barclays all of its banking operations in credit cards, loans and savings to Barclays, while retaining other activities of Tesco Bank including insurance, automatic teller machines, travel money and gift cards. The supermarket noted that these businesses are capital-light, profitable, and have a strong connect to its core retail offer.

Barclays will pay about GBP600 million for the business, which has been in operation for more than 25 years. Tesco noted it will receive about GBP1 billion in cash in total, including a special dividend of GBP250 million paid by Tesco Bank back in August.

Tesco shares closed marginally higher, while Barclays fell 0.6% in a tricky day for London-listed lenders.

HSBC shares fell 1.3%, weighing on the FTSE 100. NatWest, meanwhile, gave back 2.2%, before it reports annual results next week Friday.

Elsewhere in London, AIM-listed Evgen Pharma slumped 22% as it announced it has issued a notice of dispute with partner Stalicla, explaining that it has not received funds it believes it is entitled to.

"In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study.

"The phase 1b human volunteer study was completed and the clinical study report finalised in August 2023."

Evgen said it believes the "payment is now due".

"In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged," it added.

Brent oil was quoted at USD82.03 a barrel late in London on Friday, up from USD81.02 late Thursday.

On Monday, financial markets in Shanghai and Tokyo are closed for the Chinese New Year and National Day holidays, respectively.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.